{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:22:51Z","timestamp":1787016171309,"version":"build-2736575974"},"reference-count":0,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2017,10,25]],"date-time":"2017-10-25T00:00:00Z","timestamp":1508889600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["K23 AI114994"],"award-info":[{"award-number":["K23 AI114994"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transplant Infectious Dis"],"published-print":{"date-parts":[[2017,12]]},"abstract":"Abstract<\/jats:title>\n \n Hematopoietic stem cell transplant (\n HSCT<\/jats:styled-content>\n ) recipients are uniquely threatened by the emergence of multidrug\u2010resistant (\n MDR<\/jats:styled-content>\n ) bacteria because these patients rely on immediate active antimicrobial therapy to combat bacterial infections. This review describes the epidemiology and treatment considerations for three challenging\n MDR<\/jats:styled-content>\n bacterial pathogens in\n HSCT<\/jats:styled-content>\n recipients:\n MDR<\/jats:styled-content>\n Enterobacteriaceae, including extended\u2010spectrum \u03b2\u2010lactamase (\n ESBL<\/jats:styled-content>\n )\u2010producing and carbapenem\u2010resistant Enterobacteriaceae (\n CRE<\/jats:styled-content>\n ),\n \n P<\/jats:styled-content>\n seudomonas aeruginosa\n <\/jats:italic>\n , and vancomycin\u2010resistant\n Enterococcus<\/jats:italic>\n (\n VRE<\/jats:styled-content>\n ). These bacteria are common causes of infection in this population and bacteremias caused by these organisms are associated with high mortality rates. Carbapenems remain the treatments of choice for serious infections due to\n ESBL<\/jats:styled-content>\n \u2010producing Enterobacteriaceae in\n HSCT<\/jats:styled-content>\n recipients. Administration of \u03b2\u2010lactam agents as an extended infusion is associated with improved outcomes in patients with severe infections caused by\n \n P<\/jats:styled-content>\n .\u00a0aeruginosa\n <\/jats:italic>\n . Older agents used for the treatment of\n CRE<\/jats:styled-content>\n and\n MDR<\/jats:styled-content>\n \n P<\/jats:styled-content>\n .\u00a0aeruginosa\n <\/jats:italic>\n infections, such as polymyxins and aminoglycosides, have major limitations. Newer agents, such as ceftazidime\u2010avibactam and ceftolozane\u2010tazobactam have great potential for the treatment of\n \n K<\/jats:styled-content>\n lebsiella pneumoniae\n <\/jats:italic>\n carbapemenase\u2010producing\n CRE<\/jats:styled-content>\n and\n MDR<\/jats:styled-content>\n \n P<\/jats:styled-content>\n .\u00a0aeruginosa\n <\/jats:italic>\n , respectively, but more pre\u2010clinical and clinical data are needed to better evaluate their efficacy. Daptomycin dosages \u22658\u00a0mg\/kg\/day are recommended to treat\n VRE<\/jats:styled-content>\n infections in this population, particularly in the setting of increasing daptomycin resistance. Strategies to prevent these infections include strict adherence to recommended infection control practices and multidisciplinary antimicrobial stewardship. Last, gastrointestinal screening to guide empirical therapy and the use of polymerase chain reaction\u2010based rapid diagnostics may decrease the time to administration of appropriate therapy for these infections, thereby leading to improved outcomes.\n <\/jats:p>","DOI":"10.1111\/tid.12762","type":"journal-article","created":{"date-parts":[[2017,8,17]],"date-time":"2017-08-17T03:21:30Z","timestamp":1502940090000},"source":"Crossref","is-referenced-by-count":91,"title":["Multidrug\u2010resistant Enterobacteriaceae,\n \n P<\/scp>\n seudomonas aeruginosa\n <\/i>\n , and vancomycin\u2010resistant\n Enterococcus<\/i>\n : Three major threats to hematopoietic stem cell transplant recipients"],"prefix":"10.1111","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4711-5334","authenticated-orcid":false,"given":"Michael J.","family":"Satlin","sequence":"first","affiliation":[{"name":"Transplantation\u2010Oncology Infectious Diseases Program Division of Infectious Diseases Weill Cornell Medicine New York NY USA"},{"name":"Weill Cornell Medical Center New York\u2010Presbyterian Hospital New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Walsh","sequence":"additional","affiliation":[{"name":"Transplantation\u2010Oncology Infectious Diseases Program Division of Infectious Diseases Weill Cornell Medicine New York NY USA"},{"name":"Weill Cornell Medical Center New York\u2010Presbyterian Hospital New York NY USA"},{"name":"Department of Pediatrics and Microbiology & Immunology Weill Cornell Medicine New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,10,25]]},"container-title":["Transplant Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Ftid.12762","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/tid.12762","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T23:08:33Z","timestamp":1696028913000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/tid.12762"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,25]]},"references-count":0,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["10.1111\/tid.12762"],"URL":"https:\/\/doi.org\/10.1111\/tid.12762","archive":["Portico"],"relation":{},"ISSN":["1398-2273","1399-3062"],"issn-type":[{"value":"1398-2273","type":"print"},{"value":"1399-3062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,25]]},"article-number":"e12762"}}